The ubiquitin-proteasome system (UPS) is the main cellular proteolytic system responsible for the degradation of normal and abnormal (e.g. oxidised) proteins. Under catabolic conditions characterised by chronic inflammation, the UPS is activated resulting in proteolysis, muscle wasting and impaired muscle function. Milk proteins provide sulphur-containing amino acid and have been proposed to affect muscle inflammation. However, the response of the UPS to aseptic inflammation and protein supplementation is largely unknown. The aim of this study was to investigate how milk protein supplementation affects UPS activity and skeletal muscle function under conditions of aseptic injury induced by intense, eccentric exercise. In a double-blind, cross-over, repeated measures design, eleven men received either placebo (PLA) or milk protein concentrate (PRO, 4×20 g on exercise day and 20 g/d for the following 8 days), following an acute bout of eccentric exercise (twenty sets of fifteen eccentric contractions at 30°/s) on an isokinetic dynamometer. In each trial, muscle biopsies were obtained from the vastus lateralis muscle at baseline, as well as at 2 and 8 d post exercise, whereas blood samples were collected before exercise and at 6 h, 1 d, 2 d and 8 d post exercise. Muscle strength and soreness were assessed before exercise, 6 h post exercise and then daily for 8 consecutive days. PRO preserved chymotrypsin-like activity and attenuated the decrease of strength, facilitating its recovery. PRO also prevented the increase of NF-κB phosphorylation and HSP70 expression throughout recovery. We conclude that milk PRO supplementation following exercise-induced muscle trauma preserves proteasome activity and attenuates strength decline during the pro-inflammatory phase.

Glioblastoma remains a clinical challenge in spite of years of extensive research. Novel approaches are needed in order to integrate the existing knowledge. This is the potential role of mathematical oncology. This paper reviews mathematical models on glioblastoma from the clinical doctor's point of view, with focus on 3D modeling approaches of radiation response of in vivo glioblastomas based on contemporary imaging techniques. As these models aim to provide a clinically useful tool in the era of personalized medicine, the integration of the latest advances in molecular and imaging science and in clinical practice by the in silico models is crucial for their clinical relevance. Our aim is to indicate areas of GBM research that have not yet been addressed by in silico models and to point out evidence that has come up from in silico experiments, which may be worth considering in the clinic. This review examines how close these models have come in predicting the outcome of treatment protocols and in shaping the future of radiotherapy treatments.

Avloniti, A, Chatzinikolaou, A, Fatouros, IG, Avloniti, C, Protopapa, M, Draganidis, D, Stampoulis, T, Leontsini, D, Mavropalias, G, Gounelas, G, and Kambas, A. The acute effects of static stretching on speed and agility performance depend on stretch duration and conditioning level. J Strength Cond Res 30(10): 2767-2773, 2016-Although static stretching (SS) is an integral part of physical preparation before training and competition, its usefulness in regards to power performance improvement has been questioned. The aim of this study was to investigate the effect of 6 SS durations on speed and agility performance. According to a cross-over design, 34 trained men (age, 20.5 ± 1.4 years; height, 1.81 ± 0.2 m; weight, 77.2 ± 2.6 kg; body fat, 8.2 ± 2.6%) participated in a control session (no stretch) and 6 experimental conditions (10, 15, 20, 30, 40, and 60 seconds) performed in a randomized order. Performance in speed (10 and 20 m) and agility (T-test) was measured after the control and experimental conditions. Static stretching, consisting of stretches for hip extensors, hip adductors, knee extensors, knee flexors, and ankle sole flexors, was performed after light cardiovascular exercise (8 minutes). A 1-way repeated-measures analysis of variance showed that speed was improved only by SS of short duration (15/20 seconds), whereas agility remained unaffected by all SS trials. When participants' speed and agility level was taken into account, it was revealed that only those of moderate performance demonstrated an improved speed (in 15- and 20-second trials) and agility (in 10- and 15-second trials) performance. These results suggest that short-duration SS protocols induce an acute improvement of speed and agility performance, whereas longer-duration SS protocols have neither positive nor negative effect. Furthermore, it seems that individuals of lower speed and agility performance level are more likely to benefit by a short-duration SS protocol.

Non-small cell lung cancer patients with brain metastases have a multitude of treatment options, but there is currently no international and multidisciplinary consensus concerning their optimal treatment. Local therapies have the principal role, especially in symptomatic patients. Advances in surgery and radiation therapy manage considerable local control. Systemic treatments have shown effect in clinical trials and in real life clinical settings; yet, at present, this is restricted to patients with asymptomatic or stable intracranial lesions. Targeted agents can have a benefit only in patients with EGFR mutations or ALK rearrangement. Immunotherapy has shown impressive results in patients with PD-L1 expression in tumor cells. Its effects can be further enhanced by a synergy with radiotherapy, possibly by increasing the percentage of responders. The present review summarizes the need for more effective systemic treatments, so that the increased intracranial control achieved by local treatments can be translated in an increase in overall survival.

No abstract